Medtronic | January 11, 2022
Medtronic plc, a global leader in healthcare technology,today announced it has received approval fromJapan'sMinistry of Health, Labor and Welfare for the sale and reimbursement of the Micra™ AV Transcatheter Pacing System (TPS), and the company will launch the product this month.
This approval expands the number of patients inJapan– one of the largest markets in the world – who are eligible to receive the Micra TPS, the world's smallest pacemaker. The Micra AV is indicated for the treatment of patients with AV block, a condition in which the electrical signals between the chambers of the heart (the atria and the ventricle) are impaired. The Micra TPS is the first-ever leadless pacemaker; its first version (the Micra VR) was approved inJapanin 2017 for patients who only require single-chamber pacing.
"Pacemakers have made significant progress over their approximately 60-year history, including miniaturization, improvements in pacing technology, MRI compatibility, and remote monitoring," explainedKyoko Soejima, professor of cardiovascular internal medicine at Kyorin University Hospital and a member of the Micra TPS Global Clinical Trial steering committee. "The first Micra system transformed the concept of pacemakers by eliminating surgical pockets and leads, and Micra AV promises to deliver the benefits of leadless pacing to a larger number of patients because ventricular pacing can be performed synchronously with the atrium."
Historically, patients with AV block have been treated with traditional dual-chamber pacemakers which are implanted in the upper chest, under the skin below the collar bone, and connected to the heart using thin wires called "leads." Identical in size and shape to the original Micra TPS, Micra AV has several additional algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providing "AV synchronous" pacing therapy to patients with AV block.
The Micra AV approval is based on data from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study, which evaluated the safety and effectiveness of accelerometer-based atrial sensing algorithms. The study evaluated the ability of the Micra's internal sensor to monitor and detect atrial contractions and enable coordinated pacing between the atrium and ventricle, thereby providing AV synchrony.
"Since introducing the first battery-powered external pacemaker in 1957 to the innovative Micra leadless pacemaker portfolio, Medtronic continues to pioneer pacing innovations for physicians and their patients."
Rob Kowal, M.D., Ph.D., chief medical officer of the Cardiac Rhythm Management business at Medtronic
About the Micra Transcatheter Pacing Systems (TPS)
The Micra TPS received CE Mark inApril 2015and U.S. FDA approval in 2016. Comparable in size to a large vitamin, Micra is less than one-tenth the size of traditional pacemakers yet delivers advanced pacing technology to patients via a minimally invasive approach. During the implant procedure, the device is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device.
Unlike traditional pacemakers, Micra does not require leads or a surgical "pocket" under the skin, so potential sources of complications related to leads and pockets are reduced, and there is no visible sign of the device.
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered inDublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
AdhereHealth | December 18, 2021
AdhereHealth, a healthcare technology leader in medication adherence insights and health outcomes, has entered into a strategic partnership with Hero, the market leader in digital in-home care. This new agreement enables AdhereHealth to deploy Hero's digital in-home care platform to help high-risk, high-cost, chronically ill patients adhere to complex medication regimens.
Hero's platform includes a connected smart pill dispenser, which automatically sorts and dispenses medications according to a patient's unique medication schedule. Hero's connected app then tracks what a patient took and when, and sends real-time alerts to the patient's care team if a dose is missed or a medication is ready for refill. Hero continually monitors the patient's medication inventory and facilitates real-time medication reconciliation and synchronization.
"Combining Hero's industry-leading medication management platform with AdhereHealth's advanced technologies and its nationwide AdhereRx digital pharmacy creates the first complete lifecycle medication management service," said Kal Vepuri, founder and CEO of Hero. "Our partnership will also simultaneously improve patient safety by focusing on medication management, further support caregivers and help people take more control of their health," added Mr. Vepuri.
AdhereHealth's digital pharmacy, AdhereRx, leverages data analytics to identify and prioritize vulnerable populations most at risk for nonadherence or drug safety problems. Trained pharmacists then connect via phone with patients to conduct comprehensive medication reviews and address social determinants of health (SDOH) that might get in the way of medication adherence.
"Hero's patient-centric technology will enable care managers, providers and health plans to remotely monitor medication intake, providing real-time visibility into how patients are adhering to medication regimens at home. Combined with our medication synchronization technologies and our nationwide AdhereRx digital pharmacy solution, we can drive better patient experience and improve value-based outcomes for vulnerable populations."
Jason Z. Rose, CEO of AdhereHealth
Poor medication adherence is a leading cause of re-hospitalizations and ER visits, especially among the elderly and those with chronic conditions. The financial impact is significant: medication nonadherence accounts for 16% of U.S. healthcare spending annually, accounting for more than half a trillion dollars.
Hero is a leading digital in-home care platform delivering the first end-to-end medication management service for patients and caregivers. Hero's solution includes its award-winning smart pill dispenser, medication management app, automatic refills with free delivery and 24/7 live support. Since launching in 2018, Hero has dispensed more than 70 million medications. Hero is used as a care management solution by individuals, caregivers and medical providers.
AdhereHealth delivers purpose-built, innovative technology solutions to improve quality of care, medication adherence, and cost outcomes – all with an emphasis on overcoming social determinants of health (SDOH) and improving patient experience. AdhereRx, an AdhereHealth digital pharmacy, provides high-risk, underserved patients with personalized pharmacy services that drive medication compliance and reduce unnecessary utilization costs. This unique combination of predictive analytics, intelligent clinical workflow software and proactive telepharmacy outreach performed by a nationwide team of licensed clinicians addresses an estimated half a trillion dollars of unnecessary annual medical costs attributed to medication adherence issues. Today, the Adhere™ Platform touches nearly 30 million patients across dozens of health plans, self-insured employers and other risk-bearing entities.
Future Health | March 02, 2021
Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited.
Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software.
Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”.
Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need.
Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”.
Future Health is an independent exhibition and conference organiser, based in London in the UK.
For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: firstname.lastname@example.org or to sign up to the Future Health platform, register at www.futurehealthinnovations.com
GIANT Health | October 13, 2021
Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021
Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision.
GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform.
Learn more about Digital Therapeutics.Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs?Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021.
Come join us in person or remotely.Early Bird tickets are now available.
CLAIM YOUR TICKET HERE
A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25
See you there!
GIANT Health Events Ltd
+44 20 8144 9779